Tags
cartilage surgery
Tags
osteoarthritis treatment
136 results found in 61ms
When cartilage repair is the right choiceWhen cartilage repair is the right choice
Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.Cartilage repair is suited to younger, active patients with isolated damage in otherwise healthy joints where conservative care has not worked. It is mechanistically impossible when underlying bone is worn smooth, degeneration spans multiple compartments, or malalignment and instability persist uncorrected.
Can ChondroFiller delay joint replacement?Can ChondroFiller delay joint replacement?
An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.An injectable collagen scaffold called ChondroFiller recruits the patient's own repair cells to regenerate cartilage in 30–45 minutes. Clinical trials show IKDC score improvements averaging 32.4 points — nearly double the threshold for clinically significant change — when administered in early focal cartilage damage where joint space remains.
ChondroFiller vs hyaluronic acid for cartilage repairChondroFiller vs hyaluronic acid for cartilage repair
ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.ChondroFiller repairs focal cartilage lesions by recruiting the patient's own cells; hyaluronic acid eases broad osteoarthritis by restoring synovial fluid. These injections treat fundamentally different conditions, and selecting the wrong one offers little clinical value.
Knee cartilage repair versus stem cell therapyKnee cartilage repair versus stem cell therapy
Established cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.Established cartilage repair using autologous chondrocytes shows 10–17 year durability for focal knee defects; mesenchymal stem cell therapies have not been tested in large-scale trials against them.
ChondroFiller injection versus knee replacement for focal defectsChondroFiller injection versus knee replacement for focal defects
ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.ChondroFiller, a gelling collagen scaffold that recruits the patient's own cells to repair cartilage, suits isolated focal defects; knee replacement addresses widespread multi-compartment osteoarthritis.
OCA vs MACI for large knee cartilage defectsOCA vs MACI for large knee cartilage defects
MACI (matrix-induced autologous chondrocyte implantation) is a surface repair requiring intact subchondral bone; osteochondral allograft (OCA) replaces both cartilage and bone. When knee cartilage defects breach underlying bone, OCA addresses what MACI cannot.MACI (matrix-induced autologous chondrocyte implantation) is a surface repair requiring intact subchondral bone; osteochondral allograft (OCA) replaces both cartilage and bone. When knee cartilage defects breach underlying bone, OCA addresses what MACI cannot.
What the ChondroFiller evidence actually showsWhat the ChondroFiller evidence actually shows
ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.ChondroFiller's reoperation rate of 3–8% substantially outperforms microfracture (41%) and ACI/MACI (37%), reflecting its mechanism: the scaffold supports hyaline-like cartilage repair rather than the fibrocartilage scar tissue that other approaches produce.
How single-stage ACI differs from MACIHow single-stage ACI differs from MACI
MACI repairs cartilage defects over two operations, with weeks between them for external cell expansion; STACi compresses the entire process—harvesting, processing, and implantation—into a single surgical session.MACI repairs cartilage defects over two operations, with weeks between them for external cell expansion; STACi compresses the entire process—harvesting, processing, and implantation—into a single surgical session.
ChondroFiller and Arthrosamid serve different knee conditionsChondroFiller and Arthrosamid serve different knee conditions
ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.ChondroFiller recruits progenitor cells to rebuild focal cartilage defects, whilst Arthrosamid provides permanent cushioning for diffuse osteoarthritis by integrating into the joint capsule; the choice between them follows from what MRI reveals about the damage pattern, not from symptom severity.
ChondroFiller vs PRP for focal cartilage defectsChondroFiller vs PRP for focal cartilage defects
Focal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlyingFocal cartilage defects and diffuse cartilage loss are different problems requiring different solutions. ChondroFiller, a collagen scaffold, physically occupies and stabilises focal voids, recruiting repair cells over 12–24 months. PRP releases growth factors to reduce inflammation but cannot fill a structural gap. Imaging reveals which mechanism addresses the patient's underlying problem.
ChondroFiller or Arthrosamid for your kneeChondroFiller or Arthrosamid for your knee
ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.ChondroFiller repairs focal cartilage defects via a collagen scaffold, and Arthrosamid provides cushioning by integrating into the synovial lining — because they target different anatomical structures, the MRI scan, not patient preference, determines which injection is appropriate.
OATS or microfracture for active knee patientsOATS or microfracture for active knee patients
Microfracture improves early but deteriorates progressively beyond two years because it deposits fibrocartilage, whilst OATS transplants intact cartilage that remains stable long-term.Microfracture improves early but deteriorates progressively beyond two years because it deposits fibrocartilage, whilst OATS transplants intact cartilage that remains stable long-term.
136 results found in 61ms